Ranibizumab outperforms laser in improving diabetic macular edema

08/26/2013 | MedPage Today (free registration)

Data on diabetic macular edema patients showed 49.1% of those on ranibizumab monotherapy attained at least a 5-point improvement in National Eye Institute Visual Functioning Questionnaire 25 composite scores after 12 months, compared with 42.7% of those on ranibizumab plus laser therapy and 30.6% of those on laser-only treatment. However, further analysis is required to determine whether the drug's benefits will be sustained during the three-year study period, researchers reported in JAMA Opthalmology.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations